Miscellaneous
INDIBA protagonista en el Economista
naveed2024-03-05T13:58:31+00:00Indiba turns 40 with a consolidated growth plan and launching the new Pharma division
The CEO of the Indiba Group reviews the current situation of the company and the plans to continue growing in turnover after 40 years leading the activity in its sector.
By Álex Soler / Estela López. Photos: eE
Not all companies get to celebrate 40 years. The world changes, technological advances, new actors appear and old leaders disappear. In an almost wild business ecosystem in which everyone competes to be the reference in their sector, celebrating four decades is, in itself, a milestone to boast about. If this age is reached as Indiba has done, being a leader in solutions for physiotherapy, aesthetic medicine, beauty and veterinary medicine, much better.
Of course, reaching 40 years old is complicated, but in a sector that is advancing rapidly thanks to research and new technologies even more so. Without a doubt, the road to this point has been full of challenges and milestones, but the future is even more exciting. In this sense, Indiba faces the immediate future with the consolidation of its growth strategy worldwide. As Remco Schmitz, CEO of the Indiba Group, admits, in 2022 the company had a turnover of approximately 50 million euros and closed 2023 with an increase of approximately 15%. According to the company, its growth plan should allow sales growth of 50% by 2025.
The growth plan of the Spanish multinational, based in Barcelona, involves expanding its leadership in international markets such as the United States, the United Kingdom and Asia, with the aim of continuing to grow above the market. For example, says Schmitz, “the US is a very important market for aesthetics, veterinary medicine and rehabilitation.” In that sense, the efforts made by Indiba have allowed us to close agreements with important athletes in the country, such as Russell Wilson, quarterback of the Denver Broncos, or the Spanish Santi Aldama, the sensation of the Memphis Grizzlies. Collaborations “that mark an exciting future by Indiba into the US rehabilitation market, strengthening the company's commitment to excellence in sports performance.”
Growing in the global market has been and continues to be the company's main objective. “70% of our business comes from outside Spain,” argues Schmitz. Currently, Indiba has a presence in more than 60 countries and direct subsidiaries in France, Italy and the United States, to which it exports its radio frequency devices from its plants in Sant Quirze del Vallès (Barcelona) and Treviso (Italy).
All of its products are developed internally and its current investments are focused, above all, “on growing in the United States, in customer service, marketing and sales, as well as the implementation of new computer systems.” Additionally, Schmitz recalls, “we have a strong focus on clinical studies in medical aesthetics.” In this field, he works together with the Ramón y Cajal Hospital and with the team of several large Spanish hospitals in tissue regeneration and analysis of the effects of radiofrequency and laser on different cell lines.
Indiba wants to strengthen its presence in several international markets, especially the United States
The company produces its devices, with its own technology, in Sant Quirze del Vallès and Treviso (Italy)
Acquisitions and new Pharma division
Indiba's expansion plan would not be understood without the acquisitions they have recently carried out, through which they have been able to start working with disruptive technologies such as the high-power laser and the blue light laser from K-Laser or the Fractional RF technology that causes tissue ablation and coagulation to reduce signs of aging and improve the texture and firmness of Reverso's skin. The latest addition has been Ona, which combines double peeling, electroporation, LED and low frequency electrotherapy to achieve a new level of health and purity in the skin. Although at the moment Schmitz explains that they are focused on these additions, “we are always looking for new opportunities to grow.
At the same time, they have also opted for their new Pharma division, through which they have developed nutricosmetics and a line of body and facial cosmetics, to treat aging and a series of pathologies. The Pharma division's products are divided into two sales channels. On the one hand, the current channel in which Indiba devices are found, to complement and enhance current treatments, and, on the other, a new channel, the pharmaceutical, in which they hope to soon introduce and generate greater recognition of brand. “The objectives of the new pharma division are to increase recognition of the Indiba brand, further improve the brand experience with innovative products and connect with our customers,” details Schmitz. “With this division we will generate recurring sales in our large installed base, while reaching new consumers will certainly bring these customers to our centers, which connects all our objectives.”
INDIBA decides to strengthen its animal health division
Indiba tiene, entre sus líneas de negocio, una división basada en medicina regenerativa denominada
“animal health”, especializada en caballos, perros y gatos. El objetivo es trasladar sus terapias basadas en radiofrecuencia y láser, exitosas en humanos, a los animales. Indiba quiere desarrollar la misma filosofía que lleva tiempo dedicada a a recuperación en las personas en el bienestar y la calidad de vida de los animales, ofreciendo unas tecnologías exclusivas con tratamientos no invasivos, indoloros y avalados científicamente.
El impulso de esta división está unida al lanzamiento de los equipos de radiofrecuencia Equus y AH-100 y la incorporación de los sistemas láser de K-Laser para pequeños y grandes animales, con la línea K-Laser Cube VET y Speciale VET. Trabajando juntas, estas dos tecnologías, dice la compañía, “reducen significativamente los tiempos de tratamiento y recuperación de las lesiones en perros, gatos, caballos y otros animales domésticos, ofreciéndoles una mejor calidad de vida”. Además, también ofrecen terapias de mantenmiento para animales en competición deportiva. Indiba garantiza que estos tratamientos “son no invasivos, indoloros avalados científicamente”.